share_log

Shareholders in Guangzheng Eye Hospital GroupLtd (SZSE:002524) Have Lost 77%, as Stock Drops 19% This Past Week

Shareholders in Guangzheng Eye Hospital GroupLtd (SZSE:002524) Have Lost 77%, as Stock Drops 19% This Past Week

廣正眼科醫院集團有限公司(SZSE:002524)的股東已經虧損了77%,股票上週下跌了19%。
Simply Wall St ·  06/07 01:37

As every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an overall portfolio. So spare a thought for the long term shareholders of Guangzheng Eye Hospital Group Co.,Ltd. (SZSE:002524); the share price is down a whopping 77% in the last three years. That would certainly shake our confidence in the decision to own the stock. And more recent buyers are having a tough time too, with a drop of 50% in the last year. Furthermore, it's down 31% in about a quarter. That's not much fun for holders.

正如每位投資者所知道的那樣,不是每次交易都能達到預期,但是重大損失確實會嚴重拖累整個投資組合。因此,請爲光正眼科集團有限公司(SZSE:002524)的長期股東着想。在過去的三年裏,股價下跌了驚人的77%。這肯定會動搖我們持有該股股票的決定。最近的買家也很困難,去年下跌了50%。此外,它在約一個季度內下跌了31%。這對持有者來說並不好玩。

If the past week is anything to go by, investor sentiment for Guangzheng Eye Hospital GroupLtd isn't positive, so let's see if there's a mismatch between fundamentals and the share price.

如果過去一週是真實的,光正眼科集團有限公司的投資者情緒並不樂觀,因此讓我們看看基本面和股價之間是否存在不匹配。

Given that Guangzheng Eye Hospital GroupLtd didn't make a profit in the last twelve months, we'll focus on revenue growth to form a quick view of its business development. Shareholders of unprofitable companies usually desire strong revenue growth. That's because it's hard to be confident a company will be sustainable if revenue growth is negligible, and it never makes a profit.

考慮到光正眼科集團有限公司過去十二個月沒有盈利,我們將關注營業收入增長,以快速了解其業務發展情況。赤字公司的股東通常希望營業收入有強勁的增長。這是因爲如果營業收入增長微不足道,從不盈利,那麼很難有信心認爲公司的持續性很高。在過去的三年裏,光正眼科集團有限公司的營業收入每年下降了2.5%。這並不是投資者通常想看到的。股價下跌21%(每年,逾三年)嚴厲提醒赤字公司必須增長營業收入。如果該企業要像投資者希望的那樣表現,顯然需要增加營業收入。不要讓股價下跌破壞你的冷靜,當你冷靜時,你會做出更好的決策。

Over the last three years, Guangzheng Eye Hospital GroupLtd's revenue dropped 2.5% per year. That's not what investors generally want to see. The share price fall of 21% (per year, over three years) is a stern reminder that money-losing companies are expected to grow revenue. This business clearly needs to grow revenues if it is to perform as investors hope. Don't let a share price decline ruin your calm. You make better decisions when you're calm.

過去三年,光正眼科集團有限公司的營業收入每年下降2.5%,這通常不是投資者希望看到的。股價下跌了21%(每年,逾三年)嚴厲提醒赤字公司必須增長營業收入。如果該企業要像投資者希望的那樣表現,顯然需要增加營業收入。不要讓股價下跌破壞你的冷靜,當你冷靜時,你會做出更好的決策。

You can see how earnings and revenue have changed over time in the image below (click on the chart to see the exact values).

你可以在下面的圖片中看到收入和營業收入隨時間的變化情況(單擊圖表可查看精確值)。

earnings-and-revenue-growth
SZSE:002524 Earnings and Revenue Growth June 7th 2024
SZSE:002524收益和營業收入增長2024年6月7日第一次公佈

If you are thinking of buying or selling Guangzheng Eye Hospital GroupLtd stock, you should check out this FREE detailed report on its balance sheet.

如果您想買賣光正眼科集團有限公司的股票,請查看其資產負債表的免費詳細報告。

A Different Perspective

不同的觀點

We regret to report that Guangzheng Eye Hospital GroupLtd shareholders are down 50% for the year. Unfortunately, that's worse than the broader market decline of 12%. Having said that, it's inevitable that some stocks will be oversold in a falling market. The key is to keep your eyes on the fundamental developments. Regrettably, last year's performance caps off a bad run, with the shareholders facing a total loss of 7% per year over five years. We realise that Baron Rothschild has said investors should "buy when there is blood on the streets", but we caution that investors should first be sure they are buying a high quality business. I find it very interesting to look at share price over the long term as a proxy for business performance. But to truly gain insight, we need to consider other information, too. Consider for instance, the ever-present spectre of investment risk. We've identified 1 warning sign with Guangzheng Eye Hospital GroupLtd , and understanding them should be part of your investment process.

遺憾的是,光正眼科集團有限公司的股東今年下跌了50%。不幸的是,這比整個市場下跌的12%還要糟糕。儘管如此,在下跌的市場中股票被過度賣出的情況是不可避免的。關鍵是要密切關注基本面的發展。遺憾的是,去年的表現還是讓人失望,五年來,股東面臨着每年7%的總虧損。我們意識到羅斯柴爾德男爵曾說過投資者應該「在大街上有流血時買入」,但我們提醒投資者首先要確認他們正在購買高質量的企業。我認爲長期股價是業務表現的代理,這非常有趣。但要真正獲得洞察力,我們還需要考慮其他信息。比如,一直存在的投資風險。我們已經確定了光正眼科集團有限公司的1個警告標誌,了解它們應該是您的投資過程的一部分。

If you like to buy stocks alongside management, then you might just love this free list of companies. (Hint: many of them are unnoticed AND have attractive valuation).

如果您喜歡與管理層一起購買股票,那麼您可能會喜歡這個公司的免費列表。 (提示:其中許多公司不爲人注意且具有吸引力的估值。)

Please note, the market returns quoted in this article reflect the market weighted average returns of stocks that currently trade on Chinese exchanges.

請注意,本文引用的市場回報反映了目前在中國交易所上市的股票的市場加權平均回報。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對本文有反饋?關於內容有所顧慮?直接和我們聯繫。或電郵 editorial-team (at) simplywallst.com。
這篇文章是Simply Wall St的一般性文章。我們根據歷史數據和分析師預測提供評論,只使用公正的方法論,我們的文章並不意味着提供任何金融建議。文章不構成買賣任何股票的建議,也不考慮您的目標或您的財務狀況。我們的目標是帶給您基本數據驅動的長期關注分析。請注意,我們的分析可能不考慮最新的價格敏感公司公告或定性材料。Simply Wall St沒有任何股票頭寸。

声明:本內容僅用作提供資訊及教育之目的,不構成對任何特定投資或投資策略的推薦或認可。 更多信息
    搶先評論